PARP inhibitors have been shown to have specific efficacy against tumours with BRCA1/2 mutations, leading to the subsequent success of the use of PARP inhibitors in the treatment of certain tumours with BRCA mutation and HR deficiency 50. This evidence concerns the gene BRCA1 and neoplasm.